Phase 2 Colorectal Cancer Trial, RecruitingNCT07235293Sponsor: Kahr Bio Australia Pty LtdCondition: Colorectal Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT07235293 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People aged 18 or older who are expected to live for more than 3 months
People who have been diagnosed with a specific type of colorectal cancer (confirmed by tissue testing) that cannot be removed by surgery, has certain molecular features (known as MSS and/or pMMR), and has continued to grow or could not be tolerated after previous treatments — with no more than 3 prior rounds of treatment received
People whose cancer can be measured on scans according to a standard set of imaging guidelines (confirm with trial site)
Who may not be able to join:
People who have cancer that has spread to the brain or spinal cord, unless it has been stable for at least 2 months after treatment and no longer requires steroids
People who are still experiencing side effects rated moderate or higher from a previous cancer treatment
People with a past or current history of an autoimmune disease or a condition that affects the immune system
People who have had another type of cancer within the 3 years before starting the trial
People who are currently using or have recently used certain other medications, including specific anticancer drugs, some medications that interact with a liver enzyme called CYP3A4, or immune-modifying therapies (confirm specific medications with trial site)
People with a known allergy or sensitivity to any of the trial's study compounds or materials
People whose routine blood test results show clinically significant abnormalities (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Chris O'brien Lifehouse, Camperdown, New South Wales
Westmead Hospital, Westmead, New South Wales
Icon Cancer Centre, South Brisbane, Queensland
Flinders Medical Centre SA, Bedford Park, South Australia
Monash Health, Clayton, Victoria
Footscray Hospital - Western Health, Footscray, Victoria
Austin Health, Heidelberg, Victoria
Alfred Hospital, Melbourne, Victoria
Sunshine Hospital - Western Health, Saint Albans, Victoria
Sir Charles Gairdner Hospital, Nedlands, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07235293
Sponsor: Kahr Bio Australia Pty Ltd
Phase: Phase 2
Status: Recruiting
Condition: Colorectal Cancer
Trial contact: +972 54 749 1753
More information: https://clinicaltrials.gov/study/NCT07235293
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People aged 18 or older who are expected to live for more than 3 months
People who have been diagnosed with a specific type of colorectal cancer (confirmed by tissue testing) that cannot be removed by surgery, has certain molecular features (known as MSS and/or pMMR), and has continued to grow or could not be tolerated after previous treatments — with no more than 3 prior rounds of treatment received
People whose cancer can be measured on scans according to a standard set of imaging guidelines (confirm with trial site)
Who may not be able to join:
People who have cancer that has spread to the brain or spinal cord, unless it has been stable for at least 2 months after treatment and no longer requires steroids
People who are still experiencing side effects rated moderate or higher from a previous cancer treatment
People with a past or current history of an autoimmune disease or a condition that affects the immune system
People who have had another type of cancer within the 3 years before starting the trial
People who are currently using or have recently used certain other medications, including specific anticancer drugs, some medications that interact with a liver enzyme called CYP3A4, or immune-modifying therapies (confirm specific medications with trial site)
People with a known allergy or sensitivity to any of the trial's study compounds or materials
People whose routine blood test results show clinically significant abnormalities (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Kahr Bio Australia Pty Ltd
Registry
ClinicalTrials.gov
Start date
16 January 2026
Est. completion
30 September 2026
Where this trial is recruiting
🇦🇺 Australia
🇺🇸 United States
11 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To determine Median overall survival (mOS) in participants treated with the combination of DSP107 and atezolizumab versus fruquintinib.
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.